AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05625711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The endovascular interventional surgical instrument control system
Description: The endovascular interventional surgical instrument control system is based on the analysis of the operation behavior of doctors and their assistants in the process of manual intervention. It simulates the coordinated movement of four manipulators, completes the advance and retreat of the catheter and guide wire cavity, and realizes the different actions of wire feeding along the tube, wire feeding along the wire, wire twisting coordination, wire replacement, stent release, etc.
Study NCT06402747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75mg once daily
Study NCT06402747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: Cilostazol 200mg per day
Study NCT05874128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prospective evaluation of HeartFocus Device (Software)
Description: The primary objective of the study is to evaluate if exams, performed with the HeartFocus software by novices, are of sufficient quality to analyze visually
Study NCT06012591 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality improvement recommendations (action plans)
Description: Developed and implemented at facility level to address key quality gaps emerging from the baseline assessment
Study NCT06544798 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV2-hAQP1
Description: Administration of a prespecified concentration of AAV2-hAQP1 via Stensen's duct to each parotid gland
Study NCT06309576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting-refeeding cycle
Description: Participants will be maintained in metabolic chambers and exposed to 1 day of energy balance with a standard diet, 2 days of fasting (only water), and 2 days of ad-libitum refeeding using a liquid diet provided in hydration bladders to avoid portion control.
Study NCT06523088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN20
Description: Six dose levels of PN20 will be evaluated
Study NCT06224556 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Brief-MPI assessment (based on the Comprehensive Geriatric Assessment); Personalized Prevention Program
Description: Patients will be evaluated at baseline and at 6 and 12 months after the baseline through the CGA, the Resilience Scale (RS-14 items) and the Psychological General Wellbeing Index short form.~The prevention program will be received at the baseline, so at the two follow-ups patients wiil asked the adherence to it and the level of satisfaction (Client Satisfaction Questionnaire - 8 items).~Saliva sample will be collected and analyzed.
Study NCT06390150 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spinal Cord Stimulation
Description: The spinal cord stimulator is an implantable pulse generator connected to electrodes with leads that stimulate the spinal cord. The device is programmed to deliver therapeutic stimulation to treat pain.
Study NCT06390150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: The spinal cord stimulator is an implantable pulse generator connected to electrodes with leads that stimulate the spinal cord. The device is programmed to deliver therapeutic stimulation to treat pain.
Study NCT05045443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Tumeric curcumin 500 mg per oral capsule of Puritans Pride company supplement
Study NCT05045443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: As per institution protocol for Standard of nutritional Care
Study NCT05045443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: As per institution protocol for Standard of nutritional Care
Study NCT04856267 — intervention group
Intervention type: DEVICE
Intervention: LINQ device - implantable cardiac monitor - referred to in the application as implantable loop recorder or ILR)
Description: Implantation of an implantable cardiac monitor device (brand name LINQ device, Medtronic) will be performed under local anaesthetic using an aseptic sterile technique. They will undergo frequent follow-up and monitoring for arrhythmias through remote monitoring of the device
Study NCT05505435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depot-Medroxyprogestereone Acetate
Description: subcutaneous depot medroxyprogesterone acetate
Study NCT05505435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depot-Medroxyprogestereone Acetate
Description: intramuscular depot medroxyprogesterone acetate
Study NCT05519917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Subjects will receive evaluations at the beginning of treatment, after every three cycles and at the end of the whole study.
Study NCT06580015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET-CT
Study NCT06580015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flotufolastat F-18 Gallium
Description: Given IV
Study NCT06580015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Undergo X1 RMRS PET-CT
Study NCT06580015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-CT
Study NCT03950193 — intervention group
Intervention type: OTHER
Intervention: Questionnaires to evaluate psychic development of the child
Description: Child Behaviour Checklist. This test, completed by parents and with 52 questions, is designed to screen children at high risk for emotional problems, mood disorders, anxiety, pervasive developmental problems, attention deficit and hyperactivity, antonymic reactions (oppostion, provocation) and sleep problems.
Study NCT05599529 — intervention group
Intervention type: OTHER
Intervention: Differential attainment
Description: Differential attainment related to covid, ethnicity and international graduate status
Study NCT05660746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RoadMAB
Description: The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.
Study NCT05660746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Conventional dosing. Induction: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance: 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL.~Precision dosing. Induction: 5-12.5 mg/kg at 0, 2, and 6 weeks to target a week6 concentration of 18-24 μg/mL with dosing support provided by the RoadMABTM clinical decision support tool. Maintenance: 5-15 mg/kg every 4-8 weeks to achieve apriori pharmacokinetic and pharmacodynamic targets (CRP, disease activity scores and fecal calprotectin) with dosing support provided by the RoadMABTM clinical decision support tool.
Study NCT05660746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Conventional dosing. Induction: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance: 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL.~Precision dosing. Induction: 5-12.5 mg/kg at 0, 2, and 6 weeks to target a week6 concentration of 18-24 μg/mL with dosing support provided by the RoadMABTM clinical decision support tool. Maintenance: 5-15 mg/kg every 4-8 weeks to achieve apriori pharmacokinetic and pharmacodynamic targets (CRP, disease activity scores and fecal calprotectin) with dosing support provided by the RoadMABTM clinical decision support tool.
Study NCT05285878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fingolimod
Description: 0.5 mg daily
Study NCT05285878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mg daily
Study NCT06523088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of PN20
Study NCT04468776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem, as prescribed by physician
Study NCT04468776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: Zolpidem, as prescribed by physician
Study NCT04468776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: 6-week internet CBT-I multi-component intervention (SHUTi) including sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention
Study NCT04468776 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: 6-week internet CBT-I multi-component intervention (SHUTi) including sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention
Study NCT04468776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Description: Trazodone, as prescribed by physician
Study NCT04468776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: Trazodone, as prescribed by physician
Study NCT04678453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK01
Description: Patient-specific ex vivo expanded autologous natural killer cells
Study NCT03877874 — intervention group
Intervention type: DRUG
Intervention: Aironyl syrup(Terbutaline sulfate) + Epidrone syrup(Dexamethone)
Description: Aironyl syrup(Terbutaline sulfate ................. 1.5mg) 0.075-0.29 mg/ kg body weight 3 times daily Apidone syrup(Dexamethone) (0.02 to 0.3 mg per kilogram (kg) of body weight per day, divided and taken 3 or 4 times a day)
Study NCT06206733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASKB589
Description: ASKB589 will be administered as a minimum 3-hour IV infusion
Study NCT06206733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered as a minimum 2-hour IV infusion
Study NCT06206733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered as a minimum 2-hour IV infusion
Study NCT06206733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered orally twice daily (bid).
Study NCT06206733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine will be administered orally twice daily (bid).
Study NCT06206733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be administered every 3 weeks Intravenous infusion on day 1 of each cycle.
Study NCT06206733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tislelizumab
Description: Tislelizumab will be administered every 3 weeks Intravenous infusion on day 1 of each cycle.
Study NCT06206733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a minimum 3-hour IV infusion
Study NCT06358313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40mg
Description: The atorvastatin group consisted of 300 patients who received 40 mg daily atorvastatin for 3 months, an open-label aspirin at a loading dose of 75 to 300 mg, and then 75 mg daily till the end of the 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
Study NCT06358313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: The rosuvastatin group consisted of 300 patients who received 40 mg daily rosuvastatin for 3 months, an open-label aspirin at a loading dose of 75 to 300 mg, and then 75 mg daily till the end of the 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
Study NCT05085964 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: RNA antisense oligonucleotide for intravitreal injection
Description: QR-421a will be first administered to the fellow eye (as defined in the preceding study), and will be repeated every 6 months.~Treatment of the study eye (as defined in the preceding study) can commence 3 months (9 months for subjects from study PQ-421a-001) after the treatment of the fellow eye has been initiated and will be repeated every 6 months as well.~Continued subject treatment in this study will be pursued provided that the benefit-risk balance is positive for the individual subject.
Study NCT05707637 — intervention group
Intervention type: OTHER
Intervention: Ablation
Description: Unipolar and bipolar ablation
Study NCT06442553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GRR laser
Description: A total of 15 sessions were applied to each patient for three weeks, five times per week.
Study NCT06442553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Description: A total of 10 sessions, five sessions per week, were applied
Study NCT06442553 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nd:YAG laser
Description: A total of 10 sessions, five sessions per week, were applied
Study NCT05784233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relevance (Likelihood Salient Item is Target)
Description: The proportion of trials, when the salient visual item is present in the array, where the salient item is the search target.
Study NCT06143618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: escape room games
Description: The escape room game will include a patient scenario of four female patients who are victims of violence and apply to different clinics. Necessary equipment and materials will be provided and stations will be established where four female patients who are victims of violence will be evaluated. In the game, each student will contact the patient at only one station and evaluate signs and symptoms of violence. The activities at the stations will be carried out together as a group. The group, which completes the tasks and activities and collects the puzzle pieces that will lead to the code of the lock, will complete the puzzle and enter the number codes on it into the key of the locked box on the table (4 numerical codes received), open the box and get the message 'you can escape'. The group with the most time left at the end of the game will come first and will be rewarded.
Study NCT06143618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: role playing
Description: In the role play application, there will be scenarios of four female patients who are victims of violence and apply to different clinics. Before the role play activities, students will be asked to form groups of 4-5 people, and each week, a group will be asked to choose one of the four scenarios given by lot and improvise the case-based role play activity within 40 minutes. Before the role play application, the materials that may be required for the students (clothes, materials, etc.) and the preparation of the environment (hospital, polyclinic, etc.) will be provided by the researchers in accordance with the activity to be enacted. At the end of the role play activities, students will be able to express, evaluate and discuss their feelings and thoughts within and between groups.
Study NCT00105859 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education and Counseling
Study NCT05810012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PENG block
Description: 10ml of 0.125% isobaric bupivacaine injected
Study NCT05810012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FICB Block
Description: 20ml of 0.125% isobaric bupivacaine injected
Study NCT06256601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theracal (calcium silicate)
Description: selective removal to soft dentin, restorations with calcium silicate
Study NCT06256601 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dycal (calcium hydroxide)
Description: selective removal to soft dentin, restoration with calcium hydroxide
Study NCT05304130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Otilimab
Description: Otilimab will be administered via pre-filled syringe.
Study NCT05504980 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repositioning
Description: Patients in the intervention group will be given 30 degrees right lateral, supine, and 30 degrees left lateral positions, 1 hour apart, respectively.
Study NCT05969041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-302 (A)
Description: MT-302 is an investigational drug
Study NCT06314438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Care Project
Description: Caregivers will be administered the Family Care Project workbook.
Study NCT06198231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: Pilates exercises
Study NCT06198231 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility ,strength and endurance excercises
Description: flexibility ,strength and endurance excercises
Study NCT05394870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual lymphatic drainage (massage)
Description: Patients will begin treatment with manual lymphatic drainage in the affected extremity. In this context, while the patients are in the supine hook position, lymph drainage will be applied first to the neck and then to the abdomen. After the stimulation of the central lymph nodes, the lymph circulation will be increased by stimulating the axillary lymph nodes of the relevant region. First, the proximal part will be drained and it will be advanced towards the distal. Drainage will be repeated depending on the edema at the distal forearm-wrist level.
Study NCT05394870 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Splint treatment
Description: The splint routinely given to patients diagnosed with mild to moderate carpal tunnel syndrome will be given to both groups in these patients
Study NCT05394870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Splint treatment
Description: The splint routinely given to patients diagnosed with mild to moderate carpal tunnel syndrome will be given to both groups in these patients
Study NCT04298125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise in Pregnancy
Description: Women in this group will participate in psychical activity 3 times per week in their community setting.
Study NCT05073900 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rhomboid intercostal block
Description: two regional anesthesia block techniques are applied
Study NCT05073900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhomboid intercostal block
Description: two regional anesthesia block techniques are applied
Study NCT02309203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FRED
Description: Flow Re-Direction Endoluminal Device
Study NCT05730985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Miotrof® formula
Description: 1 sachet per day for 4 months
Study NCT05730985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo formula
Description: 1 sachet per day for 4 months
Study NCT06302712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Islamically Integrated Psychotherapy
Description: Traditional Islamically Integrated Psychotherapy for OCD. We will be using the culturally adapted module of TIIP that is translated into the Urdu language for Pakistan Muslims with OCD. The treatment module is mainly based on four domains Nafs (Behavior), Ihsas (Emotions), Aql (Thought), and Ruh (Spirituality). The session will be conducted in an individual format, with eight sessions, and the intervention will be conducted by a certified therapist in TIIP.
Study NCT06531096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: v-DOT
Description: Video directly observed therapy
Study NCT03900611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: peripheral electrical stimulation
Description: The subjects will undergo 8-week home-based peripheral electrical simulation on the median nerve. The peripheral electrical simulation will be performed once a day for 30 minutes. The stimulation will be active or sham depend on the group assignment.
Study NCT03900611 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: peripheral electrical stimulation
Description: The subjects will undergo 8-week home-based peripheral electrical simulation on the median nerve. The peripheral electrical simulation will be performed once a day for 30 minutes. The stimulation will be active or sham depend on the group assignment.
Study NCT06113627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Therapeutic Exercise
Description: Strength exercises will be aimed at large muscle groups, such as the shoulder, chest, back and also muscle groups of the lower extremities. In the initial 2 weeks, intervention will start with low intensities of around 55-65% of 1RM, which allows to perform around 15-20 repetitions. The first week there will be performed 2 series, while in the second week it will be 3 series.~Moderate intensity in the 2nd week, corresponding to 65-75% of 1RM and allowing for around 8-12 repetitions. 3 series will be maintained throughout this period of time.In addition to the progressive change in intensity, throughout the intervention the load will be increased by 5-10% when the patient performs the exercise too easily or when they can perform more repetitions than estimated. Rest between sets will be 2-3 minutes.
Study NCT05020639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3820 tablets
Description: TQB3820 is a novel cereblon-modulating agent.